COVID Support
India Denies Permission For Sputnik Light Phase 3 Trials
-
ByStartupStory | July 1, 2021
India’s drug regulator denied permission to pharmaceutical company Dr Reddy’s to conduct phase three trials for Sputnik Light in India on Wednesday. As per TOI, sources have claimed that the Central government Subject Expert Committee (SEC), which comes under the drug regulator, did not find any ‘scientific rationale’ to conduct the trials. Sputnik Light has been developed by the Russian Ministry of Health, the Gamaleya National Research Centre of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF). After launching Sputnik V, Russia had introduced Sputnik Light. It is a single-dose vaccine with an efficacy of 79.4 percent, the launch of which was announced on 6 May, by the Russian Direct Investment Fund (RDIF).
The Russian Direct Investment Fund had earlier said that according to real-world data collected by the Ministry of Health of the Buenos Aires province (Argentina) the Russian Sputnik Light Coronavirus Vaccine shows 78.6 percent to 83.7 percent efficacy among the elderly. According to the data from over 186,000 people aged 60-79, more than 40,000 of whom received a shot of Sputnik Light (first dose of Sputnik V) as part of the mass-scale civil vaccination program, the infection rate between 21st and 40th day from the date of receiving the first dose was only 0.446 per cent.
On the other side, the infection rate among the unvaccinated adult population was 2.74 percent for a comparable period. The safety, efficacy, and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.
Also Read
-
-
Clean-label food brand Anveshan has raised Rs 150 crore (nearly $16 million) in a Series B funding round led by Vertex Ventures Southeast Asia & India. The round also saw participation from International Finance Corporation (IFC), Swiggy co-founder Sri Harsha Majety, and existing investors including Wipro Consumer Care Ventures, Titan Capital Winners Fund, Force Ventures, and boAt co-founders Aman Gupta and Sameer Mehta. Entrackr had exclusively reported the development last week. According to Entrackr’s estimates, the funding valued the company at over $90 million. The fresh capital will be used to strengthen manufacturing capabilities, accelerate product development, expand offline distribution, and deepen its digital presence. The company also plans to invest in sourcing infrastructure, procurement systems, quality assurance, and testing capabilities while expanding partnerships with micro entrepreneurs and traditional producers. Founded in 2020 by Kuldeep Parewa, Akhil Kansal, and Aayushi Khandelwal, Anveshan sells minimally processed food products including A2 bilona ghee, cold-pressed oils, raw honey, atta, and other traditional nutrition-focused products. The startup operates through a network of rural producers and micro entrepreneurs across the country. Anveshan claims to be operating at an annual revenue run rate of Rs 280-300 crore and is targeting Rs 1,000 crore in revenue over the next 24-30 months. The company plans to expand its atta portfolio, strengthen its owned digital channels, scale offline distribution, and continue investing in product innovation. For the fiscal year ended March 2025, Anveshan reported a 64.6% increase in operating revenue to Rs 77.08 crore from Rs 46.84 crore in FY24. Its losses widened to Rs 11.88 crore in FY25 from Rs 5.74 crore in the previous fiscal year....
Follow Startup Story
